Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing

General Inclusion Criteria:

• Subject must be at least 18 years of age.
• Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the XIENCE V EECS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
• Subject must have significant coronary artery stenosis (>50% by visual estimate)
• Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia. In subjects with coronary artery stenosis > 75%, evidence of myocardial ischemia does not have to be documented.
• Subjects must be an acceptable candidate for Coronary Artery Bypass Graft (CABG) surgery.

Angiographically Inclusion Criteria

• Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥ 2.25 mm and ≤ 4.25 mm.
• Target lesion(s) must be amenable for percutaneous coronary intervention

General Exclusion Criteria:

• The patient has a known hypersensitivity or contraindication to any of the following medications (heparin, aspirin, clopidogrel, sirolimus, everolimus, Contrast media
• Systemic (intravenous) Sirolimus, everolimus use within 12 months.
• Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
• History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.
• Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
• Current known current platelet count <100,000 cells/mm3 or Hgb <10 g/dL.
• An elective surgical procedure is planned that would necessitate interruption of clopidogrel during the first 12 months post enrollment.
• Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
• Patients who have received any stent implantation in the target vessel prior to enrollment.
• Patients with LVEF<25% or those with cardiogenic shock
• Patients with myocardial infarction within 72 hours
• Creatinine level ≥ 3.0mg/dL or dependence on dialysis.
• Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values).

Angiographic Exclusion Criteria

• Patients with significant left main coronary artery stenosis
• Patients who's target lesion has in-stent restenosis at the stented segment of drug-eluting stents or bare metal stents
• Target lesions with chronic total occlusion
• True bifurcation lesions requiring two stents